Vertex Pharmaceuticals Inc (VRTX)
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
- Symbol
- VRTX
- Exchange
- Nasdaq
- Sector
- Healthcare
- Industry
- Biotechnology
- Market cap
- $129.94B
- 52 week range
- 392.5 - 560.25
Valuation
- Share price
- $506.74 (close of 2026-10-01)
- P/E (TTM)
- 29.61x
- Price to book
- 6.42x
- Price to free cash flow
- 34.23x
- Enterprise value
- $125.78B
- Book value per share
- $79.92
Price performance
| Period | Change |
|---|---|
| 1 day | -3.07% |
| 5 days | -2.99% |
| 1 month | -7.47% |
| 3 months | +1.75% |
| 6 months | +13.30% |
| Year to date | +11.77% |
| 1 year | +25.37% |
| 3 years | +45.72% |
| 5 years | +180.98% |
| 10 years | +481.06% |
| All time | +11160.89% |
Members of Congress who disclosed VRTX trades
David Taylor · Jefferson Shreve · Lisa McClain · Byron Donalds · Alan Armstrong · Julia Letlow · Tommy Tuberville
Super investors holding VRTX
Tweedy Browne (Tweedy Browne Company LLC)
Profitability and growth
- Return on equity
- 21.18%
- Return on invested capital
- 22.31%
- Return on assets
- 15.42%
- Return on capital employed
- 19.16%
- Gross margin
- 86.24%
- Net margin
- 32.94%
- EBITDA margin
- 36.52%
- Revenue growth
- 8.90%
- Net income growth
- 838.09%
- Free cash flow growth
- 504.13%
Cash flow and balance sheet
- Free cash flow yield (TTM)
- 2.92%
- Current ratio
- 3.19x
- Net debt to EBITDA
- -0.79x
Latest reported year
- Period end
- 2025-12-31
- Fiscal year
- 2025
- Revenue
- $12.00B
- Cost of revenue
- $1.65B
- Gross profit
- $10.35B
- EBITDA
- $4.38B
- Net income
- $3.95B
- Earnings per share
- $15.46
- Shares outstanding
- 255.70M
Income statement by year
| Period end | Revenue | Gross profit | Net income | EPS |
|---|---|---|---|---|
| 2025-12-31 | $12.00B | $10.35B | $3.95B | $15.46 |
| 2024-12-31 | $11.02B | $9.49B | -$535.60M | $-2.08 |
| 2023-12-31 | $9.87B | $8.61B | $3.62B | $14.05 |
| 2022-12-31 | $8.93B | $7.85B | $3.32B | $12.97 |
| 2021-12-31 | $7.57B | $6.67B | $2.34B | $9.09 |
| 2020-12-31 | $6.21B | $5.47B | $2.71B | $10.44 |
| 2019-12-31 | $4.16B | $3.62B | $1.18B | $4.58 |
| 2018-12-31 | $3.05B | $2.64B | $2.10B | $8.24 |
| 2017-12-31 | $2.49B | $2.21B | $263.48M | $1.06 |
| 2016-12-31 | $1.70B | $1.49B | -$112.05M | $-0.46 |
Margins and returns by year
| Period end | Gross margin | Net margin | Return on equity | Return on capital |
|---|---|---|---|---|
| 2025-12-31 | 86.24% | 32.94% | 21.18% | 22.31% |
| 2024-12-31 | 86.11% | -4.86% | -3.26% | -1.71% |
| 2023-12-31 | 87.21% | 36.68% | 20.59% | 38.30% |
| 2022-12-31 | 87.90% | 37.20% | 23.88% | 78.85% |
| 2021-12-31 | 88.06% | 30.92% | 23.19% | 56.03% |
| 2020-12-31 | 88.14% | 43.70% | 31.22% | 67.32% |
| 2019-12-31 | 86.84% | 28.27% | 19.34% | 26.84% |
| 2018-12-31 | 86.56% | 68.80% | 47.28% | 34.59% |
| 2017-12-31 | 88.95% | 10.59% | 12.90% | - |
| 2016-12-31 | 87.64% | -6.58% | -8.37% | - |
Cash and debt by year
| Period end | Cash |
|---|---|
| 2025-12-31 | $5.08B |
| 2024-12-31 | $4.57B |
| 2023-12-31 | $10.37B |
| 2022-12-31 | $10.50B |
| 2021-12-31 | $6.79B |
| 2020-12-31 | $5.99B |
| 2019-12-31 | $3.11B |
| 2019-01-01 | $3.17B |
| 2018-12-31 | $3.17B |
| 2018-01-01 | $2.09B |
Free cash flow by year
| Period end | Free cash flow | Stock-based compensation |
|---|---|---|
| 2025-12-31 | $3.19B | $685.90M |
| 2024-12-31 | -$790.30M | $698.50M |
| 2023-12-31 | $3.34B | $581.20M |
| 2022-12-31 | $3.93B | $491.30M |
| 2021-12-31 | $2.41B | $441.40M |
| 2020-12-31 | $2.99B | $429.50M |
| 2019-12-31 | $1.49B | $360.50M |
| 2018-12-31 | $1.17B | $325.05M |
| 2017-12-31 | $745.52M | $293.24M |
| 2016-12-31 | $179.54M | $240.62M |
Investor relations
Next earnings report
- Next confirmed report
- 2026-11-02
- Consensus EPS estimate
- $4.30
Past earnings dates
| Reported | Fiscal period | EPS estimate |
|---|---|---|
| 2026-08-03 | Jun/2026 | $4.15 |
| 2026-05-04 | - | - |
| 2026-02-12 | - | - |
| 2025-11-03 | - | - |
| 2025-08-04 | - | - |
| 2025-07-30 | - | - |
| 2025-05-05 | - | - |
| 2025-02-10 | - | - |
Filings and sources
- Company website
- vrtx.com
- SEC filings
- 10-K, 10-Q and 8-K on EDGAR
- Earnings calendar
- All upcoming reports
Similar companies
Moderna, Inc. (MRNA) · Regeneron Pharmaceuticals, Inc. (REGN) · Insmed Inc (INSM) · Incyte Corp (INCY) · Bio-Techne Corp (TECH) · Thermo Fisher Scientific Inc. (TMO) · Danaher Corp (DHR) · Natera, Inc. (NTRA)
Understanding these figures
Price-to-earnings ratio · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart
Explore
Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades